# SYMBRAVO® (meloxicam-rizatriptan) PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/meloxicam-rizatriptan

> The FDA approved SYMBRAVO® (meloxicam-rizatriptan), sponsored by Axsome Therapeutics, Inc. (AXSM), on January 30, 2025 for central nervous system.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: quarter only, exact day, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Verified answer

### Is SYMBRAVO® (meloxicam-rizatriptan) FDA approved?

Yes. The FDA approved SYMBRAVO® (meloxicam-rizatriptan), sponsored by Axsome Therapeutics, Inc. (AXSM), on January 30, 2025 for central nervous system. SEC Form 8-K: "On January 30, 2025, Axsome Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO® for the acute treatment of migraine with or without aura in adults." [Calendar and source filings](https://sec-api.dev/pdufa/meloxicam-rizatriptan)

Source: SEC Form 8-K, accession 0000950170-25-011220, https://www.sec.gov/Archives/edgar/data/1579428/000095017025011220/axsm-20250130.htm (retrieved 2026-11-12). Last confirmed 2025-05-05. Cite: https://sec-api.dev/pdufa/meloxicam-rizatriptan#answer

## Key facts

| Field | Value |
| --- | --- |
| Drug | SYMBRAVO® (meloxicam-rizatriptan) |
| Codes |  |
| Sponsor | Axsome Therapeutics, Inc. (AXSM) https://sec-api.dev/companies/axsm/catalysts |
| Indications | [prior inadequate response to oral cgrp inhibitors](https://sec-api.dev/indications/prior-inadequate-response-to-oral-cgrp-inhibitors), [central nervous system](https://sec-api.dev/indications/central-nervous-system) |
| Modality |  |
| FDA designations | priority review |

## Timeline

### Q1 2025: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: prior inadequate response to oral CGRP inhibitors.
- First seen 2025-02-18, last confirmed 2025-02-18.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "Topline results of EMERGE Phase 3 trial of Symbravo in migraine in patients with prior inadequate response to oral CGRP inhibitors on track for 1Q 2025" https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm

### January 30, 2025: FDA approval

- Status: completed, approved. Date confidence: exact. Indication: central nervous system.
- First seen 2025-01-31, last confirmed 2025-05-05.
- SEC Form 8-K (accession 0000950170-25-011220): "On January 30, 2025, Axsome Therapeutics, Inc. issued a press release announcing that the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO® for the acute treatment of migraine with or without aura in adults." https://www.sec.gov/Archives/edgar/data/1579428/000095017025011220/axsm-20250130.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-011220): "NEW YORK, January 30, 2025 (Globe Newswire) - Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced that the U.S. Food and Drug Administration (FDA) has approved SYMBRAVO® (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.1 SYMBRAVO represents a novel multi-mechanistic approach to treating migraine that targets multiple pathways underlying a migraine attack." https://www.sec.gov/Archives/edgar/data/1579428/000095017025011220/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-011220): "Axsome Therapeutics Announces FDA Approval of SYMBRAVO® (meloxicam and rizatriptan) for the Acute Treatment of Migraine with or without Aura in Adults" https://www.sec.gov/Archives/edgar/data/1579428/000095017025011220/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-021801): "On January 30, 2025, the U.S. Food and Drug Administration (FDA) approved Symbravo for the acute treatment of migraine with or without aura in adults." https://www.sec.gov/Archives/edgar/data/1579428/000095017025021801/axsm-ex99_1.htm
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "In January 2025, the U.S. Food and Drug Administration (FDA) approved SYMBRAVO for the acute treatment of migraine with or without aura in adults." https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm

### Feb 2025: topline data readout

- Status: completed, positive. Date confidence: month. Stage: 3.
- First seen 2025-05-05, last confirmed 2025-05-05.
- Press release filed with the SEC (EX-99) (accession 0000950170-25-063158): "Migraine: In February 2025, Axsome announced positive topline results from the EMERGE Phase 3 open-label trial of SYMBRAVO in patients experiencing inadequate response to oral CGRP inhibitors." https://www.sec.gov/Archives/edgar/data/1579428/000095017025063158/axsm-ex99_1.htm

### April 30, 2026: PDUFA date

- Status: scheduled. Date confidence: exact.
- First seen 2026-02-23, last confirmed 2026-02-23.
- Press release filed with the SEC (EX-99) (accession 0001193125-26-062421): "SYMBRAVO® 4Q and full year 2025 net product sales of $4.1 million and $6.6 million, respectively sNDA for AXS-05 for the treatment of Alzheimer's disease agitation granted Priority Review with PDUFA target action date of April 30, 2026" https://www.sec.gov/Archives/edgar/data/1579428/000119312526062421/axsm-ex99_1.htm

## Same indication

- [AUVELITY (dextromethorphan-bupropion)](https://sec-api.dev/pdufa/dextromethorphan-bupropion) (AXSM)
- [Reboxetine](https://sec-api.dev/pdufa/reboxetine) (AXSM)
- [SUNOSI® (solriamfetol)](https://sec-api.dev/pdufa/solriamfetol) (AXSM)

Calendar months: [April 2026](https://sec-api.dev/fda-calendar/2026-04)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/meloxicam-rizatriptan.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "SYMBRAVO® (meloxicam-rizatriptan) PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/meloxicam-rizatriptan

```bibtex
@misc{secapidev_pdufa_meloxicam_rizatriptan_20261116,
  title        = {SYMBRAVO® (meloxicam-rizatriptan) PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/meloxicam-rizatriptan}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_meloxicam_rizatriptan_20261116","title":"SYMBRAVO® (meloxicam-rizatriptan) PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/meloxicam-rizatriptan","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
